194 related articles for article (PubMed ID: 38147019)
1. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.
Nie C; Xu W; Guo Y; Gao X; Lv H; Chen B; Wang J; Liu Y; Zhao J; Wang S; He Y; Chen X
BMC Cancer; 2023 Dec; 23(1):1239. PubMed ID: 38102538
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
Xu J; Zhang H; Zhang L; Chu X; Li Y; Li G; Nie C; Wang M; Guo Y
Cancer Med; 2023 Dec; 12(23):21159-21171. PubMed ID: 37935113
[TBL] [Abstract][Full Text] [Related]
4. HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.
Chen M; Yao K; Cao M; Liu H; Xue C; Qin T; Meng L; Zheng Z; Qin Z; Zhou F; Liu Z; Shi Y; An X
Cancer Immunol Immunother; 2023 Jul; 72(7):2309-2318. PubMed ID: 36897337
[TBL] [Abstract][Full Text] [Related]
5. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.
Zhu K; Chang Y; Zhao D; Guo A; Cao J; Wu C; Guan Y; Ding S
Front Pharmacol; 2024; 15():1355081. PubMed ID: 38455962
[No Abstract] [Full Text] [Related]
6. Disitamab Vedotin: First Approval.
Deeks ED
Drugs; 2021 Nov; 81(16):1929-1935. PubMed ID: 34661865
[TBL] [Abstract][Full Text] [Related]
7. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study.
Wei Y; Zhang R; Yu C; Hong Z; Lin L; Li T; Chen J
Front Pharmacol; 2023; 14():1230395. PubMed ID: 37645442
[No Abstract] [Full Text] [Related]
8. RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study.
Wang P; Xia L
BMC Cancer; 2023 Nov; 23(1):1083. PubMed ID: 37946161
[TBL] [Abstract][Full Text] [Related]
9. Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report.
Zheng Y; Xue YY; Zhao YQ; Chen Y; Li ZP
Front Immunol; 2023; 14():1254812. PubMed ID: 37901233
[TBL] [Abstract][Full Text] [Related]
10. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.
Wang Y; Gong J; Wang A; Wei J; Peng Z; Wang X; Zhou J; Qi C; Liu D; Li J; Lu M; Lu Z; Cao Y; Yuan J; Zhang R; Fang J; Zhang X; Shen L
EClinicalMedicine; 2024 Feb; 68():102415. PubMed ID: 38235421
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study.
Li C; Sun L; Liu Z; Sun H; Wang X; Yu Q; Yu Z
Am J Cancer Res; 2024; 14(2):869-879. PubMed ID: 38455400
[TBL] [Abstract][Full Text] [Related]
12. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study.
Zhao H; Xu Z; Li C; Xu T; Zhang J; Jiao J; Yang B; Qin R; Yang L; Qin W; Jing Y
Adv Ther; 2024 Feb; 41(2):857-866. PubMed ID: 38048019
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review.
Qi X; Guo J; Zhou X; Sun L; Lin J; Huang Z; Chen H; Lin L
Heliyon; 2022 Sep; 8(9):e10581. PubMed ID: 36185140
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
Sheng X; Wang L; He Z; Shi Y; Luo H; Han W; Yao X; Shi B; Liu J; Hu C; Liu Z; Guo H; Yu G; Ji Z; Ying J; Ling Y; Yu S; Hu Y; Guo J; Fang J; Zhou A; Guo J
J Clin Oncol; 2024 Apr; 42(12):1391-1402. PubMed ID: 37988648
[TBL] [Abstract][Full Text] [Related]
16. Preclinical safety profile of disitamab vedotin:a novel anti-HER2 antibody conjugated with MMAE.
Jiang J; Li S; Shan X; Wang L; Ma J; Huang M; Dong L; Chen F
Toxicol Lett; 2020 May; 324():30-37. PubMed ID: 31877330
[TBL] [Abstract][Full Text] [Related]
17. Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study.
Wang A; Chen M; Li D; Shi J; Tang W; Zhang Z; Ren S
Clin Genitourin Cancer; 2024 Jun; 22(3):102085. PubMed ID: 38636170
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of immune checkpoint inhibitors in solid tumor patients combined with chronic coronary syndromes or its risk factor: a nationwide multicenter cohort study.
Liu C; Ruan Y; Huang R; Fang L; Wu T; Lv Y; Cui L; Liao Y; Wang B; Chen Z; Su D; Ma Y; Han S; Guan X; Cui J; Yao Y; Wang Y; Wang M; Liu R; Zhang Y
Cancer Immunol Immunother; 2024 Jun; 73(8):159. PubMed ID: 38850359
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
20. Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study.
Chu X; Qiang H; Xie M; Li X; Zhao J; Wu Y; Zhou J; Ye J; Zhao C; Han C; Chu T; Su C
Cancer Immunol Immunother; 2022 Jul; 71(7):1625-1631. PubMed ID: 34743223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]